Invivyd (IVVD) Q4 2025 earnings review
Commercial Acceleration and Massive Cash Raise Secure the Bridge to VYD2311 Data
Invivyd ended 2025 with strong execution, posting a 31% sequential jump in PEMGARDA revenue to $17.2 million. However, the real story is the balance sheet: after raising over $200 million in H2 2025 and aggressively cutting R&D spend, the company is now fully funded past its most critical catalyst—the mid-2026 Phase 3 readouts for its next-generation antibody, VYD2311. Management is effectively using the PEMGARDA launch to build a commercial foundation while waiting for VYD2311 to unlock the much larger 'vaccine alternative' market.
🐂 Bull Case
The Q1 2025 decision to internalize the sales force initially caused a revenue dip, but has now driven consecutive sequential growth, culminating in a record $17.2M in Q4. The commercial infrastructure is scaling successfully.
By raising >$200M in the second half of the year, Invivyd ended 2025 with $226.7M in cash. This eliminates the short-term financing overhang and ensures the company can independently reach the mid-2026 pivotal data readouts.
🐻 Bear Case
Despite PEMGARDA's growth, the company's valuation is almost entirely dependent on the DECLARATION and LIBERTY trial results for VYD2311 in mid-2026. Any clinical or regulatory slip-up here would be devastating.
In early 2025, management explicitly targeted profitability by the end of H1 2025. This was quietly missed. While burn has decreased drastically, the company is still generating net losses (~$11M in Q4 2025).
⚖️ Verdict: ⚪
Neutral/Cautiously Optimistic. The company executed flawlessly on the two things it could control in H2 2025: cutting costs and raising capital. However, until the FDA validates VYD2311, the stock remains a high-stakes clinical binary event.
Key Themes
PEMGARDA Commercial Execution is Accelerating
After a rocky Q1 transition to an in-house sales force ($11.3M), revenue growth is clearly accelerating. Q4 revenue hit $17.2M, up 31% QoQ and 25% YoY. This is critical not just for cash flow, but because it builds the physical commercial plumbing (GPO contracts, infusion center relationships) required for the potential launch of VYD2311.
VYD2311: The 'Vaccine Alternative' Pivot
Management's core strategy is shifting from treating the immunocompromised to targeting broad populations suffering from 'vaccine hesitancy.' VYD2311 is the vehicle for this. The DECLARATION trial is fully enrolled, and the FDA has granted Fast Track designation. If VYD2311 can prove equivalent protection to mRNA vaccines with a vastly superior reactogenicity profile via a simple intramuscular (IM) shot, the TAM expands exponentially.
Massive Operating Leverage via R&D Cuts
Invivyd successfully reversed its cash-burn trajectory. FY25 R&D expenses collapsed to $38.3M from $137.3M in FY24. This was achieved by winding down the CANOPY trial and reducing manufacturing costs. This operating discipline is what allowed their recent capital raises to stretch the runway so deeply into 2026.
Profitability Narrative Quietly Dropped
A key contradiction to the positive financial narrative: in Q1 2025, management explicitly guided that they were 'targeting profitability by the end of the first half of 2025.' By Q2, they admitted this was missed. Now, despite $53.4M in annual revenue and slashed R&D, FY25 net loss was still $52.5M. The 'near-term breakeven' narrative has been replaced entirely by 'sufficient cash runway' commentary.
Regulatory Friction and Unusual Trial Mechanics
Invivyd has a history of friction with the FDA, notably when the FDA rejected PEMGARDA's treatment EUA expansion in early 2025. Now, the LIBERTY trial for VYD2311 introduces new complexity: head-to-head safety testing against mRNA vaccines. The FDA requested specific monitoring for myocarditis/pericarditis. Comparing a therapeutic monoclonal antibody (CDER division) alongside a vaccine (CBER division) creates elevated bureaucratic and regulatory risk.
Market Education Remains a Heavy Lift
Management continues to acknowledge that selling monoclonal antibodies requires an 'enormous amount of time' to re-educate Healthcare Providers. To achieve blockbuster status with VYD2311, the company will have to fundamentally alter primary care physician behavior to view mAbs as a first-line preventative tool rather than a niche specialty treatment.
Platform Diversification Beyond COVID
To mitigate single-virus risk, Invivyd is officially expanding its pipeline. The company selected VBY329, a potential best-in-class RSV antibody with higher in-vitro potency than standard of care, targeting an IND in 2H 2026. A preclinical measles candidate update is expected in 1H 2026. This validates the underlying antibody discovery platform.
Other KPIs
Stable/Accelerating liquidity. A massive improvement from $69.3M at the end of 2024. Invivyd raised over $200M in the second half of 2025. This cash balance essentially acts as an insurance policy, guaranteeing the company will see the other side of the VYD2311 clinical readouts without needing a distressed capital raise.
Reversing. A dramatic improvement from the -$169.9M net loss posted in FY24. The reduction was driven almost entirely by the $99M YoY drop in R&D spending, alongside a doubling of net product revenues. EPS improved from -$1.43 to -$0.30.
Guidance
The company guided that data from the fully-enrolled Phase 3 pivotal trial is expected in mid-2026. This is the central catalyst for the company. An upsizing decision to support statistical power could be made in April 2026 based on early blinded COVID event rates.
Management expects to advance its RSV prophylactic candidate to IND readiness in the second half of 2026. This signals an accelerating timeline to transform Invivyd from a COVID-only company to a broader infectious disease platform.
Key Questions
Transferability of Commercial Infrastructure
PEMGARDA is currently sold primarily to infusion centers and specialists treating the immunocompromised. If VYD2311 is approved as an intramuscular 'vaccine alternative' for the broader public, how much of your current commercial foundation is actually transferable, and how much new SG&A spend will be required to reach primary care physicians?
LIBERTY Trial Safety Dynamics
The FDA requested specific monitoring for adverse events like myocarditis in the LIBERTY trial due to the mRNA vaccine arm. If VYD2311 shows even mild reactogenicity in a head-to-head setting, how does that impact the 'superior safety' commercial narrative you are building?
Operating Expense Run-Rate
With DECLARATION fully enrolled and R&D expenses having plummeted in FY25, what is the steady-state quarterly cash burn expectation for H1 2026 prior to the data readout?